Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
Clinical trial NCT04407442 · TERMINATED
Trial details
- NCT number
- NCT04407442
- Sponsor
- University of California, San Francisco
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-30
- Primary completion
- 2023-04-30
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.